Shopping Cart 0
Cart Subtotal
USD 0

University of California - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

University of California is a public research university system that offers educational and research services. The university' services include research and teaching services, graduate, undergraduate and postgraduate courses, doctoral programs and courses, master's programs, degree programs, bachelors programs, extension courses, student exchange and transfer services. It also provides laboratory services, library services, museums, concert halls, art galleries, botanical gardens, observatories and marine centers, academic resources, continuing education courses, agricultural advice and educational programs. University of California offers faculty grant programs, fellowship programs, and faculty-led partnerships and research collaborations, among others. The university provides its services through its campuses, facilities and departments. University of California is headquartered in Bakersfield, California, the US.

University of California-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 9

University of California, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

University of California, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11

University of California, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

University of California, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13

University of California, Medical Devices Deals, 2012 to YTD 2018 15

University of California, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16

University of California, Pharmaceuticals & Healthcare, Deal Details 26

Venture Financing 26

DNAlite Therapeutics Raises USD1.5 Million in Seed Financing 26

Private Equity 28

Allogene Therapeutics Raises USD120 Million in Private Financing 28

Partnerships 30

Akili Interactive Enters into Licensing Agreement with University of California 30

PharmaResearch Products Enters into Agreement with University of California 31

Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 32

InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 33

Helperby Therapeutics Enters into Collaboration Agreement with University of California Los Angeles 34

OncoSec Medical Enters into Research Agreement with University of California 35

Vaccinex Enters into Agreement with UCLAs Jonsson Comprehensive Cancer Center 36

Protagen Enters into Agreement with University of California, San Francisco 37

INSYS Therapeutics Expands Agreement with University of California San Diego 38

Clerisy Enters into Partnership with University of California 39

Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 40

MYOS RENS Technology Enters into Research Agreement with University Of California Berkley 41

Fate Therapeutics Enters into Partnership with University of California San Diego 42

Apexigen Enters into Agreement with University of California San Francisco 43

Strata Oncology Enters into Agreement with University of California 44

Novartis Enters into Agreement with University of California 45

BrainStorm Cell Therapeutics Enters into Agreement with University of California Irvine Medical Center 46

ShangPharma Innovation Enters into Partnership with the University of California San Francisco 47

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 48

Xynomic Pharma Enters into Agreement with University of California San Francisco 49

Biomed Realty Trust Enters into Agreement with University of California San Diego 50

Galmed Pharma Enters into Agreement with University of California 51

Xcell Biosciences Enters into Partnership with University of California, San Francisco 52

Selvita Enters into Agreement with University of California, San Francisco 53

Natera Enters into Research Agreement with University of California, San Francisco 54

Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 55

University of California, Berkeley Enters into Agreement with Aduro Biotech 57

Trethera Enters into Research Agreement with University of California, Los Angeles 58

UCSF Partners with Berkeley Lights 59

NewBio Therapeutics and University of California Los Angeles Enter into Agreement 60

Janssen Pharma Enters into Agreement with University of California, San Diego 61

Bristol-Myers Squibb Enters into Research Agreement with UCLA 62

BioCision Partners with University of California 63

Color Genomics Partners with University of California Health 64

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 65

Novoheart Enters into Research Agreement with University of California Irvine 66

Celgene Partners with Recombinant Antibody Network 67

New York Blood Center Enters into Agreement with University of California 68

AccentCare Forms Joint Venture With UC San Diego Health System 69

Calico Enters into Research Agreement with QB3 70

UCSF Medical Center Forms Joint venture with John Muir Health 71

BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 72

Zymeworks Enters into Research Agreement with University of California, Los Angeles 73

Sutro Biopharma Enters into Agreement with University of California, San Francisco 74

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 75

Navidea Biopharma Amends Agreement with University of California San Francisco 76

ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 77

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 78

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 80

Centers For Therapeutic Innovation Partners with UC San Francisco 81

NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 82

OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 83

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 84

DNAnexus Enters Into Co-Development Agreement With Geisinger Health System And University of California 85

University of California Enters Into Research Agreement With Sanofi 86

Licensing Agreements 87

CavoGene LifeSciences Enters into Licensing Agreement with University of California San Diego 87

FUJIFILM Cellular Dynamics Enters into Licensing Agreement with University of California Irvine 88

Bloom Science Enters into Licensing Agreement with UCLA 89

Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 90

Excision BioTherapeutics Enters into Licensing Agreement with University of California Berkeley 91

MonTa Biosciences Enters into Licensing Agreement with University of California and Technical University of Denmark 92

Diamyd Medical Enters into Licensing Agreement with University of California 93

Lyceum Pharma Enters into Licensing Agreement with University of California Irvine 94

Vanda Pharma Enters into Licensing Agreement with UC San Francisco 95

CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 96

Fortis Therapeutics Enters into Licensing Agreement with University of California, San Francisco 98

RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 99

Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 100

MatriSys Bioscience Enters into Licensing Agreement with University of California, San Diego 101

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 102

Oncternal Therapeutics Enters into Licensing Agreement with University of California 103

Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 104

Pionyr Immunotherapeutics Enters into Licensing Agreement with University of California and University of Toronto 105

Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 106

Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 107

Sage Therapeutics Enters into Licensing Agreement with University of California 108

Calico Life Sciences Enters into Licensing Agreement with University of California, San Francisco 109

Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 110

Novoheart Enters into Licensing Agreement with University of California Davis 111

MiNA Therapeutics Enters into Licensing Agreement with University of California San Francisco 112

Batu Biologics Enters into Licensing Agreement with University of California, San Diego 113

Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 114

Silarus Therapeutics Receives Rights from University of California 115

Dermala Enters into Licensing Agreement with Regents of the University of California 116

Countervail Enters into Licensing Agreement with University of California 117

Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 118

Novoheart Enters into Licensing Agreement with University of California Irvine 119

Merganser Biotech Enters into Licensing Agreement with Regents of the University of California 120

Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis 121

Curtana Pharma Enters into Licensing Agreement with University of California San Diego 122

SomPharma Enters into Licensing Agreement with University of California, San Diego 123

University of California San Francisco Enters into Licensing Agreement with Mitokinin 124

CohBar Enters Into Licensing Agreement With Regents Of The University Of California 125

Abreos Biosciences Enter into License Agreement with University of California San 126

Caribou Biosciences Enters into Licensing Agreement with Regents of the University of California and University of Vienna 127

Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 128

Fibrocell Science Enters Into Licensing Agreement With University of California 129

Aduro BioTech Enters into Licensing Agreement with UCB 130

DesignMedix Enters into Licensing Agreement with University of California, San Diego 131

Pliant Therapeutics Enters into Licensing Agreement with UC San Francisco 132

PsychoGenics Enters into Licensing Agreement with University of California, San Diego 133

PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 134

SeraCare Life Sciences Enters into Licensing Agreement with University of California 135

Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 136

PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 137

PaxVax Enters into Licensing Agreement with University Of California, San Diego 138

Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 139

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 140

Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 141

BioTime Enters Into Licensing Agreement With University of California, Los Angeles 142

Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 143

Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 144

Islet Sciences Enters Into Licensing Agreement With University of California 145

Equity Offering 146

Antiva Biosciences Spin Out from University of California San Diego 146

Asset Transactions 147

Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 147

University of California - Key Competitors 149

University of California - Key Employees 150

University of California - Locations And Subsidiaries 151

Head Office 151

Other Locations & Subsidiaries 151

Recent Developments 153

Legal and Regulatory 153

Sep 10, 2018: CRISPR Therapeutics, Intellia Therapeutics & Caribou Biosciences provide update on US federal circuit decision upholding the ruling by US patent and trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology 153

Government and Public Interest 154

Sep 19, 2018: NIH funds study to prevent, treat HIV among adolescents in poor countries 154

Dec 11, 2017: $5 million grant from NIH will enable UCLA to develop new models for autism 155

Oct 16, 2017: Researchers Show the Potential of Precision Medicine for Treating Rare Cancers 156

Sep 20, 2017: Discovery helps improve accuracy of CRISPR-Cas9 gene editing 157

Sep 20, 2017: Space research institute awards 10 research grants 159

Sep 11, 2017: New University of California Cancer Consortium to tackle states second leading cause of death 161

Sep 05, 2017: Zika virus shrinks brain tumours in lab tests 162

Apr 21, 2017: NIH Funds Seven International Centers of Excellence for Malaria Research 163

Mar 15, 2017: UCLA researchers finding holds promise for treating children after brain injuries 165

Jan 09, 2017: UCLA to play a leadership role in $21.7M NIH grant for epilepsy research 167

Product News 168

Oct 10, 2017: Allergy Drug Improves Function in Patients with Chronic Injury from Multiple Sclerosis 168

Jul 20, 2017: Immune-Cell Numbers Predict Response to Combination Immunotherapy in Melanoma 170

Other Significant Developments 172

Sep 10, 2018: UC vows to protect groundbreaking CRISPR invention despite court decision 172

Appendix 173

Methodology 173

About GlobalData 173

Contact Us 173

Disclaimer 173


List Of Figure

List of Figures

University of California, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of California, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of California, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of California, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of California, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

University of California, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 11

University of California, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

University of California, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13

University of California, Medical Devices Deals, 2012 to YTD 2018 15


List Of Table

List of Tables

University of California, Pharmaceuticals & Healthcare, Key Facts 2

University of California, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

University of California, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11

University of California, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

University of California, Deals By Therapy Area, 2012 to YTD 2018 13

University of California, Medical Devices Deals, 2012 to YTD 2018 15

University of California, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16

DNAlite Therapeutics Raises USD1.5 Million in Seed Financing 26

Allogene Therapeutics Raises USD120 Million in Private Financing 28

Akili Interactive Enters into Licensing Agreement with University of California 30

PharmaResearch Products Enters into Agreement with University of California 31

Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 32

InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 33

Helperby Therapeutics Enters into Collaboration Agreement with University of California Los Angeles 34

OncoSec Medical Enters into Research Agreement with University of California 35

Vaccinex Enters into Agreement with UCLAs Jonsson Comprehensive Cancer Center 36

Protagen Enters into Agreement with University of California, San Francisco 37

INSYS Therapeutics Expands Agreement with University of California San Diego 38

Clerisy Enters into Partnership with University of California 39

Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 40

MYOS RENS Technology Enters into Research Agreement with University Of California Berkley 41

Fate Therapeutics Enters into Partnership with University of California San Diego 42

Apexigen Enters into Agreement with University of California San Francisco 43

Strata Oncology Enters into Agreement with University of California 44

Novartis Enters into Agreement with University of California 45

BrainStorm Cell Therapeutics Enters into Agreement with University of California Irvine Medical Center 46

ShangPharma Innovation Enters into Partnership with the University of California San Francisco 47

University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 48

Xynomic Pharma Enters into Agreement with University of California San Francisco 49

Biomed Realty Trust Enters into Agreement with University of California San Diego 50

Galmed Pharma Enters into Agreement with University of California 51

Xcell Biosciences Enters into Partnership with University of California, San Francisco 52

Selvita Enters into Agreement with University of California, San Francisco 53

Natera Enters into Research Agreement with University of California, San Francisco 54

Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 55

University of California, Berkeley Enters into Agreement with Aduro Biotech 57

Trethera Enters into Research Agreement with University of California, Los Angeles 58

UCSF Partners with Berkeley Lights 59

NewBio Therapeutics and University of California Los Angeles Enter into Agreement 60

Janssen Pharma Enters into Agreement with University of California, San Diego 61

Bristol-Myers Squibb Enters into Research Agreement with UCLA 62

BioCision Partners with University of California 63

Color Genomics Partners with University of California Health 64

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 65

Novoheart Enters into Research Agreement with University of California Irvine 66

Celgene Partners with Recombinant Antibody Network 67

New York Blood Center Enters into Agreement with University of California 68

AccentCare Forms Joint Venture With UC San Diego Health System 69

Calico Enters into Research Agreement with QB3 70

UCSF Medical Center Forms Joint venture with John Muir Health 71

BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 72

Zymeworks Enters into Research Agreement with University of California, Los Angeles 73

Sutro Biopharma Enters into Agreement with University of California, San Francisco 74

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 75

Navidea Biopharma Amends Agreement with University of California San Francisco 76

ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 77

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 78

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 80

Centers For Therapeutic Innovation Partners with UC San Francisco 81

NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 82

OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 83

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 84

DNAnexus Enters Into Co-Development Agreement With Geisinger Health System And University of California 85

University of California Enters Into Research Agreement With Sanofi 86

CavoGene LifeSciences Enters into Licensing Agreement with University of California San Diego 87

FUJIFILM Cellular Dynamics Enters into Licensing Agreement with University of California Irvine 88

Bloom Science Enters into Licensing Agreement with UCLA 89

Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 90

Excision BioTherapeutics Enters into Licensing Agreement with University of California Berkeley 91

MonTa Biosciences Enters into Licensing Agreement with University of California and Technical University of Denmark 92

Diamyd Medical Enters into Licensing Agreement with University of California 93

Lyceum Pharma Enters into Licensing Agreement with University of California Irvine 94

Vanda Pharma Enters into Licensing Agreement with UC San Francisco 95

CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 96

Fortis Therapeutics Enters into Licensing Agreement with University of California, San Francisco 98

RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 99

Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 100

MatriSys Bioscience Enters into Licensing Agreement with University of California, San Diego 101

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 102

Oncternal Therapeutics Enters into Licensing Agreement with University of California 103

Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 104

Pionyr Immunotherapeutics Enters into Licensing Agreement with University of California and University of Toronto 105

Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 106

Global Blood Therapeutics Enters Licensing Agreement with Regents of the University of California 107

Sage Therapeutics Enters into Licensing Agreement with University of California 108

Calico Life Sciences Enters into Licensing Agreement with University of California, San Francisco 109

Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 110

Novoheart Enters into Licensing Agreement with University of California Davis 111

MiNA Therapeutics Enters into Licensing Agreement with University of California San Francisco 112

Batu Biologics Enters into Licensing Agreement with University of California, San Diego 113

Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 114

Silarus Therapeutics Receives Rights from University of California 115

Dermala Enters into Licensing Agreement with Regents of the University of California 116

Countervail Enters into Licensing Agreement with University of California 117

Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 118

Novoheart Enters into Licensing Agreement with University of California Irvine 119

Merganser Biotech Enters into Licensing Agreement with Regents of the University of California 120

Sage Therapeutics Amends Licensing Agreement with Regents of the University of California and University of California, Davis 121

Curtana Pharma Enters into Licensing Agreement with University of California San Diego 122

SomPharma Enters into Licensing Agreement with University of California, San Diego 123

University of California San Francisco Enters into Licensing Agreement with Mitokinin 124

CohBar Enters Into Licensing Agreement With Regents Of The University Of California 125

Abreos Biosciences Enter into License Agreement with University of California San 126

Caribou Biosciences Enters into Licensing Agreement with Regents of the University of California and University of Vienna 127

Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 128

Fibrocell Science Enters Into Licensing Agreement With University of California 129

Aduro BioTech Enters into Licensing Agreement with UCB 130

DesignMedix Enters into Licensing Agreement with University of California, San Diego 131

Pliant Therapeutics Enters into Licensing Agreement with UC San Francisco 132

PsychoGenics Enters into Licensing Agreement with University of California, San Diego 133

PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 134

SeraCare Life Sciences Enters into Licensing Agreement with University of California 135

Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 136

PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 137

PaxVax Enters into Licensing Agreement with University Of California, San Diego 138

Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 139

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 140

Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 141

BioTime Enters Into Licensing Agreement With University of California, Los Angeles 142

Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 143

Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 144

Islet Sciences Enters Into Licensing Agreement With University of California 145

Antiva Biosciences Spin Out from University of California San Diego 146

Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 147

University of California, Key Competitors 149

University of California, Key Employees 150

University of California, Subsidiaries 151

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

University of California, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.